SciELO - Scientific Electronic Library Online

 
vol.128 issue1Carotid endarterectomy under regional anesthesia: Initial experienceSurvival of patients with esophageal carcinoma subjected to total thoracic esophagectomy author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista médica de Chile

Print version ISSN 0034-9887

Abstract

CHAHUAN Y, Marco; CORRADI H, Luis; ROMAN A, Oscar  and  BRAVO G, Cecilia. Safety and efficacy of celiprolol in patients with chronic obstructive lung disease. Rev. méd. Chile [online]. 2000, vol.128, n.1, pp.59-63. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872000000100008.

Background: Third generation beta blockers have an intrinsic simpatico-mimetic activity and are cardioselective. Therefore, they should not have adverse bronchial effects and could even have a slight bronchodilator activity. Aim: To test the efficacy and safety of celiprolol in hypertensive patients with chronic obstructive lung disease. Patients and methods: Uncomplicated hypertensive patients with chronic obstructive lung disease received celiprolol during 12 weeks. They were subjected to monthly clinical assessment and ventilatory function was measured on the basal period and at the end of the trial. Results: During the study period, blood pressure fell significantly from 179±6/112±8 to 161±4,7/98±1.6 mmHg. No changes were observed in forced expiratory volume in 1 s or in forced expiratory flow between 25 and 75% of the vital capacity. No subjective changes in respiratory function were reported during the trial. Conclusions: No changes in ventilatory function were observed in these patients with chronic obstructive lung disease, treated with celiprolol during 12 weeks. (Rev Méd Chile 2000; 128: 59-63)

Keywords : Adrenergic beta-antagonists; Celiprolol; Lung diseases, obstructive.

        · text in Spanish

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License